GlassScriptPhysician profile
William J Hollins
NPI 1164422820
$147,470.10
in general payments reported to CMS, 2019-2025
44 companies · $1,687 in 2025
The $1,687 reported for 2025 was more than what 84% of Sleep Medicine (Internal Medicine) providers received nationally (typical 2025 total: $447).
See the full distribution for Sleep Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103K · 2020: $20K · 2021: $18K · 2022: $1,476 · 2023: $2,025 · 2024: $1,737 · 2025: $1,687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,411 · Education: $37.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,411.48 |
| Education | $37.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $34,935.87 | 2019-2022 | |
| Amgen INC. | $32,700.25 | 2019-2025 | Repatha, Repatha |
| Lilly USA, LLC | $31,145.05 | 2019-2025 | Zepbound, Mounjaro |
| Esperion Therapeutics, INC. | $14,152.95 | 2020-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11,689.19 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $7,874.11 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $5,308.79 | 2019 | |
| Jazz Pharmaceuticals INC. | $2,029.99 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $1,741.76 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,283.85 | 2019-2023 | Praluent, Evkeeza |
| Merck Sharp & Dohme LLC | $445.54 | 2019-2025 | Verquvo |
| Novo Nordisk INC | $432.88 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $411.63 | 2019-2025 | |
| Boston Scientific Corporation | $409.30 | 2019-2024 | Watchman Access System, Watchman Flx, Bodyguardian |
| Alnylam Pharmaceuticals INC. | $306.41 | 2022-2025 | Onpattro |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $292.70 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $273.32 | 2019-2025 | Wainua, Farxiga, Lokelma |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $257.24 | 2021-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $230.65 | 2023-2025 | |
| Chiesi USA, INC. | $192.47 | 2019-2021 | |
| Atricure, INC. | $141.70 | 2025 | Epi-Sense Guided Coagulation System With Visitrax, Synergy Ablation System |
| Medtronic, INC. | $131.29 | 2024 | Micra |
| Abbott Laboratories | $124.67 | 2022-2025 | Jot Dx, Thoratec Heartmate 3 Lvas Implant Kit, Amplatzer Talisman |
| Philips North America LLC | $104.91 | 2019-2023 | |
| Kiniksa Pharmaceuticals International, Plc | $96.27 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $81.87 | 2023-2024 | |
| Lundbeck LLC | $76.62 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $73.61 | 2022-2023 | Arcalyst |
| Corcept Therapeutics | $70.44 | 2025 | Korlym |
| Lexicon Pharmaceuticals, INC. | $65.12 | 2023-2024 | Inpefa |
| Kowa Pharmaceuticals America, INC. | $63.41 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $62.95 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Abiomed | $58.72 | 2024-2025 | Impella |
| Avadel Cns Pharmaceuticals, LLC | $55.94 | 2025 | Lumryz |
| Cvrx, INC. | $43.67 | 2023-2025 | Barostim Neo System |
| Bridgebio Pharma, INC. | $27.21 | 2025 | Attruby |
| Impulse Dynamics (USA) INC. | $26.79 | 2023 | Optimizer |
| Altathera Pharmaceuticals LLC | $17.44 | 2025 | Sotalol Hydrochloride |
| Irhythm Technologies, INC. | $16.38 | 2023 | Zio Xt Patch |
| Edwards Lifesciences Corporation | $12.99 | 2023 | Sapien 3 Ultra Resilia |
| Travere Therapeutics, INC. | $4.15 | 2020-2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Hollins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.